Eliem Therapeutics, Inc. financial data

Symbol
ELYM on Nasdaq
Industry
Pharmaceutical Preparations
Location
2801 Centerville Road 1 St Floor, Pmb #117, Wilmington, DE
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 4.49K % +87%
Debt-to-equity 2.3 % -47.9%
Return On Equity -47 % -28.8%
Return On Assets -46 % -31.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 67.1M shares +148%
Common Stock, Shares, Outstanding 66.8M shares +147%
Entity Public Float 13.2M USD -5.04%
Common Stock, Value, Issued 7K USD +133%
Weighted Average Number of Shares Outstanding, Basic 30.3M shares +13.1%
Weighted Average Number of Shares Outstanding, Diluted 30.3M shares +13.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 8.14M USD -56.2%
General and Administrative Expense 9.7M USD -67.5%
Operating Income (Loss) -69.5M USD -43.4%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -64.2M USD -42.8%
Earnings Per Share, Basic -2.14 USD/shares -13.8%
Earnings Per Share, Diluted -2.14 USD/shares -13.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 223M USD +782%
Marketable Securities, Current 0 USD -100%
Cash, Cash Equivalents, and Short-term Investments 124M USD -23.4%
Assets, Current 226M USD +97.8%
Operating Lease, Right-of-Use Asset 21K USD -94.4%
Other Assets, Noncurrent 0 USD -100%
Assets 226M USD +94.4%
Accounts Payable, Current 509K USD -42%
Accrued Liabilities, Current 2.95M USD +30.8%
Liabilities, Current 3.74M USD +3.4%
Operating Lease, Liability, Noncurrent 0 USD -100%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 3.74M USD -0.85%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -213M USD -43.3%
Stockholders' Equity Attributable to Parent 222M USD +97.6%
Liabilities and Equity 226M USD +94.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.82M USD +88%
Net Cash Provided by (Used in) Financing Activities 15K USD +1400%
Net Cash Provided by (Used in) Investing Activities 13.8M USD +137%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 66.8M shares +147%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 11.9M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 223M USD +782%
Deferred Tax Assets, Valuation Allowance 20.9M USD +24.4%
Deferred Tax Assets, Gross 20.9M USD +24%
Operating Lease, Liability 585K USD -15.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -64.2M USD -44.6%
Lessee, Operating Lease, Liability, to be Paid 611K USD -17.8%
Operating Lease, Liability, Current 100K USD -79.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 15K USD -95.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 342K USD +45.5%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, to be Paid, Year Three 172K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 17.1M USD +38.1%
Lessee, Operating Lease, Liability, to be Paid, Year Four 15K USD 0%
Share-based Payment Arrangement, Expense 2.84M USD -80.6%